Skip to main content
. 2021 May 15;13(10):2395. doi: 10.3390/cancers13102395

Figure 4.

Figure 4

AKT signaling pathway controls PSC proliferation and TGFβ1 secretion. (A,B) Inhibition of AKT activation after 72 h cell treatment with the PI3K/AKT pharmacological inhibitor LY 294002 (20 µM) decreased PS-1 cell proliferation. Representative Western blot of AKT reduced phosphorylation by LY 294002 treatment (Aa) and the quantification as previously described (Ab) (N = 3, *** p < 0.001, Student t-test). All values were first normalized to the referent protein GAPDH and then to the control condition, reported as mean ± SEM. Cell proliferation was evaluated after 72 h of treatment by MTT assay (N = 4, *** p < 0.001, Student t-test) (B). (C,D) Effect of AKT inhibition on TGFβ1 mRNA expression (C) and secretion (D) after 72 h LY 294002 treatment (* p < 0.05, ** p < 0.01, N = 3, Student t-test). Values were normalized to control and reported as mean ± SEM.